HansBiomed Corporation (KOSDAQ:042520)

Market Cap	320.28B
Revenue (ttm)	89.78B
Net Income (ttm)	-31.34B
Shares Out	13.69M
EPS (ttm)	-2,413.29
PE Ratio	n/a
Forward PE	28.68
Dividend	n/a
Ex-Dividend Date	n/a

Volume	183,935
Average Volume	304,478
Open	23,050
Previous Close	23,250
Day's Range	22,000 - 23,500
52-Week Range	6,180 - 38,000
Beta	2.10
RSI	33.33
Earnings Date	Feb 12, 2026

About HansBiomed

HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralized cortical bone stick; SureChip, a cancellous bone chip; OsteoGrow, a demineralized bone matrix inserter; BellaCell HD, an allograft dermal product tha...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1990
• Employees: 277
• Stock Exchange: KOSDAQ
• Ticker Symbol: 042520

Financial Performance

In 2025, HansBiomed's revenue was 89.78 billion, an increase of 10.65% compared to the previous year's 81.14 billion. Losses were -31.34 billion, 333.9% more than in 2024.